Other

Genzyme Corporation

The Johns Hopkins University

Bristol-myers Squibb Compnay

Incyte Corporation

Bristol-myers Squibb Pharma Company

University of Utah Research Foundation

Timothy C Burn

Jiacheng Zhou

Qun Li

Zhongjiang Jia

Timothy D Connors

Gregory M Landes

Mark T Keating

Michael C Sanguinetti

William R Dackowski

Mark E Curran

Carl P Decicco

Robert A Copeland

James M Trzaskos

Elizabeth C Arner

Michael A Pratta

Kimberly A Solomon

Fude Yang

Gregory G Germino

Karyn O'Neil

Ming Tao

William Frietze

Igor Splawski

Katherine W Klinger

Ronald L Magolda

Micky Daniel Tortorella

Ruiqin Liu

Feng Qian

Gregory Franklin Hollis

Krishna Vaddi

Dietmar A Seiffert

Jeffrey T Billheimer

Jordan S Fridman

Peggy Ann Scherle

Dengjin Wang

Ira B Dicker

Steven M Friedman

Qing K Wang

Phillip C Liu

Xiangdong Liu

Reid Huber

Jennifer E Kochie

Henry J George

Jeannine M Hollis

Terence J Van Raay

Leah A Breth

Terence Van Raay

Phillip C C Liu

The present disclosure relates to 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2&#x2032;:5,6]pyrido[4,3-d]pyrimidin-2-one, solid forms and polymorphs thereof, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.

Solid forms of an FGFR inhibitor and processes for preparing the same

The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.

Compositions, methods and kits relating to Her-2 cleavage

The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu-Ala. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.

Antibodies to aggrecan-degrading metalloprotease and diagnostic methods using same

The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.

KVLQT1&#x2014;a long QT syndrome gene

The present invention provides methods and compositions for treating cyst formation in PKD1-associated epithelial cells. Such methods encompass administering an isolated human PKD1 gene, or fragments of the gene, under conditions that result in expression of therapeutically effective amounts of all, or part of, the PKD1 protein. The invention also encompasses compositions for treating cyst formation associated with APKD.

Polycystic kidney disease gene

The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu -Ala . The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.

Aggrecan degrading metallo proteases

Detection of patients at risk for developing integrin antagonist/agonist mediated disease states

Diagnostic method for KVLQT1&mdash;a long QT syndrome gene

Nucleic acids encoding aggrecan degrading metallo proteases

KVLQT1&mdash;a long QT syndrome gene

KVLQT1&mdash;a long qt syndrome gene

The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes are also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.

The present invention involves isolated nucleic acid encoding human PKD1, and sequences derived therefrom. The invention also encompasses vectors comprising these nucleic acids, host cells transformed with the vectors, and methods for producing PKD1 protein or fragments thereof. In another aspect, the invention involves isolated oligonucleotides that hybridize only to the authentic expressed PKD1 gene, and not to PKD1 homologues. In yet another aspect, the invention involves isolated mutant PKD1 genes, and their cDNA cognates. Further provided are isolated oligonucleotides that discriminate between normal and mutant versions of the PKD1 gene. Methods and compositions for treating APKD or disease conditions having the characteristics of APKD are also provided.

Polycystic kidney disease gene and protein

In accordance with the present invention, there are provided isolated nucleic acids encoding a human netrin, a human ATP binding cassette transporter, a human ribosomal L3 subtype, and a human augmenter of liver regeneration as well as isolated protein products encoded thereby. The present invention provides nucleic acid probes that hybridize to invention nucleic acids as well as isolated nucleic acids comprising unique gene sequences located on chromosome 16. Further provided are vectors containing invention nucleic acids, host cells transformed therewith, as well as transgenic non-human mammals that express invention polypeptides. The present invention includes antisense oligonucleotides, antibodies and compositions containing same. Additionally, the invention provides methods for identifying compounds that bind to invention polypeptides.

Human chromosome 16 genes, compositions, methods of making and using same

Growing community of inventors

Hockessin, DE, United States of America

Timothy C Burn